The two companies have announced an alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease.
The aim is to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer’s disease. Lilly will lead clinical development, working with researchers from AstraZeneca’s Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible for manufacturing. The companies will take joint responsibility for commercialisation of AZD3293.
Under the terms of the agreement, Lilly will pay AstraZeneca up to USD 500 million in development and regulatory milestone payments. AstraZeneca expects to receive the first milestone payment of USD 50 million in the first half of 2015. The companies will share all future costs equally for the development and commercialisation of AZD3293, as well as net global revenues post-launch.